Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Trial Details

NCT ID

NCT07333261

Phase

PHASE1

Sponsor

Susan Bal

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

BMS-986453

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

Age \> 18 years with no upper age limit
NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and …
Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →